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Development of a Staphylococcus 
aureus reporter strain with click 
beetle red luciferase for enhanced 
in vivo imaging of experimental 
bacteremia and mixed infections
Robert J. Miller1, Heidi A. crosby2, Katrin Schilcher2, Yu Wang1, Roger V. ortines1, 
Momina Mazhar1, Dustin A. Dikeman1, Bret L. pinsker1, isabelle D. Brown1, Daniel p. Joyce1, 
Jeffrey Zhang1, nathan K. Archer  1, Haiyun Liu1, Martin p. Alphonse  1, Julie czupryna3, 
William R. Anderson3, nicholas M. Bernthal4, Lea fortuno-Miranda5,6, Jeff W. M. Bulte5,6,7,8,9, 
Kevin p. francis3,4, Alexander R. Horswill  2,10,14 & Lloyd S. Miller  1,11,12,13,14*
In vivo bioluminescence imaging has been used to monitor Staphylococcus aureus infections in 
preclinical models by employing bacterial reporter strains possessing a modified lux operon from 
Photorhabdus luminescens. However, the relatively short emission wavelength of lux (peak 490 nm) 
has limited tissue penetration. to overcome this limitation, the gene for the click beetle (Pyrophorus 
plagiophtalamus) red luciferase (luc) (with a longer >600 emission wavelength), was introduced singly 
and in combination with the lux operon into a methicillin-resistant S. aureus strain. After administration 
of the substrate D-luciferin, the luc bioluminescent signal was substantially greater than the lux signal 
in vitro. the luc signal had enhanced tissue penetration and improved anatomical co-registration with 
infected internal organs compared with the lux signal in a mouse model of S. aureus bacteremia with a 
sensitivity of approximately 3 × 104 cfU from the kidneys. finally, in an in vivo mixed bacterial wound 
infection mouse model, S. aureus luc signals could be spectrally unmixed from Pseudomonas aeruginosa 
lux signals to noninvasively monitor the bacterial burden of both strains. therefore, the S. aureus luc 
reporter may provide a technological advance for monitoring invasive organ dissemination during S. 
aureus bacteremia and for studying bacterial dynamics during mixed infections.
Staphylococcus aureus is a major human pathogen that causes the majority of skin infections as well as invasive 
and life-threatening infections such as bacteremia, pneumonia, surgical site infections and organ abscesses1,2. 
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S. aureus bacteremia is particularly problematic as the mortality rate has remained between 14 to 29% despite 
the use of antibiotics with coverage against antibiotic-resistant strains (such as methicillin-resistant S. aureus 
[MRSA]) and advances in supportive measures3–6. To study the pathogenesis of S. aureus infections in preclini-
cal animal models, in vivo whole animal bioluminescence imaging (BLI) has been used with bioluminescent S. 
aureus strains expressing the luxABCDE (lux) operon, adapted from the bacterial insect pathogen Photorhabdus 
luminescens7–10. For S. aureus, Gram-positive ribosomal binding sites have been introduced upstream of each 
of lux gene, resulting in the endogenous emission of bioluminescent light from live and actively metabolizing 
S. aureus bacteria11–15. A strong promoter that is active in all bacterial growth phases can be inserted upstream 
of the lux genes for improved light production13,14. Furthermore, if the lux operon construct is stably integrated 
into the bacterial chromosome or into a stable plasmid (rather than an unstable antibiotic selection plasmid13,16), 
light production is maintained in all progeny and the BLI signals highly correlate with ex vivo colony forming 
units (CFU)13,17–21. The use of in vivo BLI with bioluminescent S. aureus strains has permitted the noninvasive and 
longitudinal monitoring of the bacterial burden, which has provided key information about the infectious course 
and disease pathogenesis in skin and soft tissue infections13,17,22–26 as well as musculoskeletal infections16,19,27–34. 
In addition, this technology has been used to evaluate therapeutics, such as antibiotics18,20,35–39, active and passive 
vaccines29,40,41 and other antimicrobials37,42 as well as S. aureus-specific diagnostic imaging probes27,43,44.
Although in vivo BLI in conjunction with S. aureus bioluminescent strains has been used in many preclinical 
models of infection, the light emitted from the S. aureus lux reporter strains has a relatively short wavelength 
(peak = 490 nm45), which limits light penetration through deeper tissues7,8. Therefore, in deep-seated and inva-
sive S. aureus infections, the emitted in vivo BLI signal is quenched by the surrounding tissue and no longer 
accurate as it underestimates the actual in vivo bacterial burden7,8. In addition, the light production by the S. 
aureus lux reporter strains is also limited by the metabolic activity of the bacteria and it is often difficult to detect 
dim signals from metabolically inactive bacteria such as bacteria present in biofilms38,46. Taken together, existing 
in vivo BLI approaches with S. aureus lux strains are more accurate in monitoring the in vivo bacterial burden for 
more superficial S. aureus infections such as skin and musculoskeletal infections, but its use in invasive infections 
is limited.
In the present study, we set out to improve the capability and accuracy of detecting BLI signals in invasive S. 
aureus infections. First, we further modified the lux operon for improved endogenous light production in a new 
bioluminescent S. aureus strain. Second, since the click beetle (Pyrophorus plagiophtalamus) red luciferase (luc) 
has a substantially longer emission wavelength of light (peak >600 nm) after exogenous substrate exposure47–51, 
we reasoned that a S. aureus luc reporter strain might result in better tissue penetration than a S. aureus lux 
reporter strain. Therefore, we also developed a luc construct that was introduced singly or along with the lux 
construct into a S. aureus strain to develop new lux, luc and dual lux + luc reporter S. aureus strains. The biolumi-
nescent signals from these lux and luc expressing S. aureus strains were then evaluated in vitro and in invasive (i.e., 
bacteremia) and more superficial (i.e., skin and musculoskeletal) preclinical models of S. aureus infection in vivo.
Results
Generation of a new lux expressing S. aureus strain. To generate an improved bioluminescent lux 
expressing S. aureus strain, the gene sequence luxCDABEG derived from the bioluminescent bacterial insect 
pathogen Photorhabdus luminescens was synthesized with Gram-positive ribosome binding sites at the start sites 
of each respective lux gene. This cassette has two strong promoters at the start called PCP25 and PCAP, followed 
by an excisable stem loop transcriptional terminator. Expression of the lux genes is driven by readthrough from 
these strong promoters. This complete lux cassette was cloned into plasmid pLL2952 to generate plasmid pHC125 
lux (Fig. 1A). This plasmid was integrated at the φ11 attachment site on the chromosome of the CA-MRSA 
LAC strain AH126353 to generate the new bioluminescent strain AH4807 (lux). The construct is stable without 
selection and easily moved by bacteriophage transduction to other S. aureus strains such as CA-MRSA USA400 
MW254 to generate strain AH4821 (lux) and MSSA Newman55 to generate strain AH5016 (lux).
We compared the new AH4807 (lux) against the existing bioluminescent S. aureus strains USA300 LAC::lux15, 
LAC4303 (lux)14,56 and Xen36 (lux)11 (Table 1) in terms of growth, luminescence output, and stability in vitro. 
For these comparison strains, USA300 LAC::lux was constructed by moving the original lux kanamycin resist-
ant (KanR) cassette from strain Xen2957. LAC4303 (lux) has the lux construct on an integrated plasmid on the 
bacterial chromosome of USA300 LAC, and Xen36 (lux) has the lux construct inserted on a stable plasmid in 
the methicillin-sensitive S. aureus strain Wright. All four strains grow fairly similarly, with USA300 LAC::lux 
lagging slightly behind (see Supplemental Data, Fig. S1A). LAC4303 (lux) generated the most bioluminescence 
during a 10-hour time course, followed by both AH4807 (lux) and Xen36 (lux) which behaved similarly over time 
(Fig. S1A), and finally USA300 LAC::lux had the lowest luminescence output. LAC4303 (lux) is constructed with 
a temperature-sensitive plasmid called pRP119514 and we predicted this plasmid might undergo excision from 
the chromosome at lower temperatures. Indeed, we observed significant excision rates at 30 °C as determined 
by PCR (Fig. S1B,C), which were reduced at 37 °C and non-existent at 43 °C. Despite the instability, we did not 
observe a deleterious impact on overall LAC4303 (lux) luminescence at lower temperatures. The AH4807 (lux) 
plasmid pHC125 was stable at all temperatures as anticipated (Fig. S1B,C).
Generation of luc and lux + luc expressing S. aureus strains. Since the click beetle (Pyrophorus pla-
giophtalamus) red (CBR) luciferase (luc) has a longer emission wavelength of light (peak >600 nm47–51) than lux 
(peak 490 nm45) (Table 2), we generated luc and lux + luc expressing CA-MRSA strains. The CBR luc gene was 
synthesized and cloned into the S. aureus shuttle vector pCM2853 under the control of the hprK/lgt constitutive 
promoter, generating plasmid pHC123 CBR-luc (Fig. 1B). This plasmid was then transduced into the CA-MRSA 
LAC strain to generate the luc expressing strain AH4775 (luc) and into AH4807 (lux) to generate the lux + luc 
expressing strain AH4826 (lux + luc). In addition, the luc construct was also transduced in two divergent S. 
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aureus strains, USA400 MW2 to generate AH5557 (luc) and AH5559 (lux + luc) and MSSA Newman to generate 
AH5556 (luc) and AH5558 (lux + luc).
Bacterial growth and light production of lux, luc and lux + luc S. aureus strains in vitro. Next, in 
vitro assays were performed to compare AH4807 (lux), AH4775 (luc) and AH4826 (lux + luc) against the existing 
bioluminescent S. aureus strains USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (Table 1). The lux expressing 
strains naturally emit light due to endogenous substrates produced during bacterial metabolism7–10 whereas luc 
expressing strains produce light only in the presence of an exogenous substrate, firefly D-Luciferin47–51. Therefore, 
the in vitro assays were conducted without an exogenous substrate to detect lux signals and in the presence of 
D-Luciferin (0.03–1.2 mg) to detect luc signals. To evaluate for any differences in bacterial growth, all strains 
were cultured in shaking broth in parallel wells in 96-well plates for 14 hours and absorbance at 600 nm (A600) 
Figure 1. Genetic maps of lux and luc plasmid constructs. (A) Plasmid pHC125 lux used to generate 
chromosomally integrated luxCDABEG construct. Expression is driven by the PCP25 and PCAP promoters (prom). 
Plasmid stably integrates at the phage 11 attachment site in S. aureus. (B) Plasmid pHC123 CBR-luc carrying 
constitutively expressed click beetle red luciferase (CBR-luc). Expression is driven by the Plgt promoter.
Name Genotype Features Reference
AH4775 (luc) LAC + pHC123 (CBR-luc, CamR) CBR-luc This paper
AH4807 (lux) LAC int::luxCDABEG lux This paper
AH4826 (lux + luc) LAC int::luxCDABEG pHC123 (CBR-luc, CamR) lux and CBR-luc This paper
USA300 LAC::lux LAC int::luxABCDE lux 15
LAC4303 (lux) LAC strain JE2 int::luxBADCE lux 56
Xen36 (lux) Wright (ATCC 49525) + luxABCDE (on a native plasmid) lux
11
AH4821 (lux) MW2 int::luxCDABEG lux This paper
AH5016 (lux) Newman int::luxCDABEG lux This paper
AH5556 (luc) Newman + pHC123 (CBR-luc, CamR) CBR-luc This paper
AH5557 (luc) MW2 + pHC123 (CBR-luc, CamR) CBR-luc This paper
AH5558 (lux + luc) Newman int::luxCDABEG pHC123 (CBR-luc, CamR) lux and CBR-luc This paper
AH5559 (lux + luc) MW2 int::luxCDABEG pHC123 (CBR-luc, CamR) lux and CBR-luc This paper
Table 1. S. aureus strains. CamR = chloramphenicol resistant.
Peak Reference
Lux (Photorhabdus luminescens) 490 45
Luc (CBR) + D-Luciferin 614 58
Table 2. Peak wavelengths (nm) of lux versus CBR-luc + D-Luciferin substrate.
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(Fig. 2A) and bioluminescent signals (Fig. 2B) were measured. LAC4303 (lux) was used as a comparison strain 
as it emits brighter bioluminescent signals than other existing lux strains (USA300 LAC::lux and Xen36 (lux)). 
In the presence of 0.03, 0.15 or 0.30 mg of D-Luciferin, there was no difference in absorbance among all of the 
strains. However, in the presence of 0.60 mg D-Luciferin, from 10–14 hours there was higher absorbance of 
the lux expressing strains AH4807 and Xen36 (lux) than LAC4303 (lux) (P < 0.05) whereas the absorbance of 
USA300 LAC::lux, AH4775 (luc) and AH4826 (lux + luc) did not differ compared with LAC4303 (lux). At 1.20 mg 
of D-Luciferin, from 7–14 hours Xen36 (lux) and AH4775 (luc) had higher absorbance than LAC4303 (lux) 
(P < 0.05) whereas USA300 LAC::lux and AH4826 (lux + luc) had lower absorbance) compared with LAC4303 
(lux).
Irrespective of any effects of high concentrations of D-Luciferin (0.60 and 1.20 mg) on bacterial growth in vitro, 
all concentrations of D-Luciferin tested resulted in markedly increased bioluminescent signals with the luc 
expressing strains AH4775 (luc) and AH4826 (lux + luc) strains beginning at 6 hours, peaking at 7–9 hours and 
then slightly decreasing compared with the lower bioluminescent signals of LAC4303 (lux) (which had similar 
bioluminescent signals as all of the other lux expressing strains). To evaluate the new bioluminescent constructs 
in other S. aureus strains, lux, luc and lux + luc were expressed in the MW2 and Newman backgrounds and com-
pared to LAC (see Supplemental Data, Fig. S2A,B).
Taken together, although D-Luciferin at high concentrations had some effects on bacterial growth among the 
bioluminescent S. aureus strains, D-luciferin at all concentrations tested resulted in markedly increased biolu-
minescent signals only from the luc S. aureus strains, indicating bioluminescent signals produced by luc were a 
magnitude greater than those produced by lux in vitro.
enhanced tissue penetration of luc compared with lux BLi signals in vitro. To evaluate the BLI 
signals produced by the lux versus luc constructs, AH4826 (lux + luc) was cultured overnight on bacterial culture 
plates. The plates were then imaged (IVIS Lumina IIII, PerkinElmer) with no filter (open) and with 520, 570, 620, 
670, 710 and 790 nm emission filters in the absence (—) (lux signals only) or presence (+) (lux + luc signals) of 
D-Luciferin added to the surface of the plates (Fig. 3A). With the open filter, D-Luciferin addition to AH4826 
(lux + luc) colonies on the plates resulted in markedly higher BLI signals than in absence of D-Luciferin, sug-
gesting that the light produced by luc greatly enhanced the BLI signals of lux alone. Furthermore, in the absence 
of D-Luciferin, the highest BLI signals were detected with the shortest wavelength emission filter (520 nm) and 
Figure 2. In vitro bacterial growth curves and bioluminescence signals. AH4807 (lux), AH4775 (luc), AH4826 
(lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (all 1 × 104 CFU) were cultured in 96-well plates 
without (none) and with the addition of different concentrations (0.03–1.2 mg/240 µL TSB/well) of D-Luciferin 
for 0–14 hours and absorbance at 600 nm (A600) (A) and bioluminescent signals (photons/0.1 second acquisition 
time) (B) were measured every 5 minutes on a plate reader (BioTek H1 Synergy) (n = 4 replicates with 2 
iterations).
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the signals decreased with longer emission filters with no signals detected beyond the 620 nm emission filter. In 
contrast, in the presence of D-Luciferin, the lux + luc signals peaked with the 620 nm emission filter and the BLI 
signals decreased with shorter and longer emission filters away from this peak. Taken together, the BLI signals of 
AH4826 (lux + luc) in the absence and presence of D-Luciferin are consistent with the known peak wavelengths 
of 490 nm for lux45 and 614 nm for CBR-luc in the presence of the D-Luciferin substrate58.
Given that CBR-luc signals were substantially greater and peaked at a much higher wavelength than those 
of lux, we evaluated whether the addition of D-Luciferin could enhance tissue penetration in vitro. This was 
accomplished by culturing AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) 
and Xen36 (lux) in 96-well plates without (none) or with increasing concentrations of D-Luciferin (0.03–2.4 mg) 
added to the wells (Fig. 3B). Immediately prior to imaging the plates (IVIS Lumina III), different thicknesses of 
tissue (sliced cooked ham 5.25 to 21 mm) were placed on top of the plate covers. With no tissue placed on top 
of the plates, the BLI signals could be detected from all lux strains, including AH4826 (lux + luc) followed by 
LAC4303 (lux), Xen36 (lux), AH4807 (lux) and USA300 LAC::lux. With 5.25 mm of tissue placed on top of the 
plates, lux signals from only AH4826 (lux + luc), LAC4303 (lux) and Xen36 (lux) could be detected, and with 
10.5 mm of tissue placed on top of the plates, no lux signals could be detected. With increasing concentrations of 
D-Luciferin added, both luc expressing strains AH4775 (luc) and AH4826 (luc + lux) had detectable BLI signals 
through 10.5 mm of tissue. Remarkably, with increasing concentrations of D-Luciferin, AH4826 (lux + luc) had 
BLI signals that could be detected through 15.75 and 21.0 mm of tissue. Taken together, the luc expressing strains 
AH4775 (luc) and AH4826 (luc + lux) in the presence of increasing concentrations of D-Luciferin had greater 
penetration of the BLI signals through tissue than any of the lux only expressing S. aureus strains. Moreover, 
strain AH4826 (luc + lux) had BLI signals that could be detected through greater than 2 cm of tissue.
In vivo BLi signals of lux versus luc in a mouse model of S. aureus bacteremia. To evaluate 
whether the improved tissue penetration using luc, compared with lux, in vitro (Fig. 3) occurred similarly in vivo, 
AH4826 (lux + luc) and LAC4303 (lux) were evaluated in a mouse model of S. aureus bacteremia (Fig. 4A–F). 
Both bacterial strains were inoculated intravenously at a 20–30% lethal dose (1 × 107 CFU) (Fig. S3). On day 3 
post-inoculation, the lux only representative in vivo BLI signals (i.e., no D-Luciferin administration) of AH4826 
(lux + luc) and LAC4303 (lux) were relatively dim and could be only be detected from the bladder on the ventral 
sides of the mice (Fig. 4A) and from the kidneys on the dorsal side of the mice (Fig. 4D). To evaluate the luc in 
vivo BLI signals, on day 3 post-inoculation of AH4826 (lux + luc), D-Luciferin was administered subcutaneously 
and the mice were imaged for various time points up to 65 minutes. The administration of D-luciferin resulted 
in detectable in vivo BLI signals from the bladder as well as other internal organs in the abdominal cavity such as 
the kidneys and liver (no signals were detected from the chest) (Fig. 4A,D). Regarding the timeframe for optimal 
detection of in vivo BLI signals after D-Luciferin administration, the in vivo BLI signals increased over the first 
10 minutes, peaking around 15 minutes and then remained at a similar level for up to 65 minutes, when imaging 
the mice was arbitrarily discontinued (Fig. 4B,E). Without the addition of D-Luciferin, there was no statistical 
differences in the lux in vivo BLI signals from AH4826 (lux + luc) and LAC4303 (lux) on the ventral or dorsal 
sides of the mice (Fig. 4C,F). The in vivo BLI signals from the abdominal cavity were significantly and markedly 
higher (155-fold on ventral side and 114-fold on dorsal side of the mice) with AH4826 (lux + luc) after D-luciferin 
administration compared with the lux only signals of AH4826 (lux + luc) (P < 0.01) (Fig. 4C,F). Taken together, 
administration of D-Luciferin to AH4826 (lux + luc)-infected mice resulted in a marked increase of the in vivo 
BLI signals from internal organs compared with the lux only BLI signals of AH4826 (lux + luc) or LAC4303 (lux). 
In addition, the optimal timeframe for in vivo BLI of the mice after D-Luciferin administration was ~15–25 min-
utes and this timeframe was used in subsequent experiments.
In vivo BLi signals of lux versus luc in other animal models of S. aureus infection. Since AH4826 
(lux + luc) after D-Luciferin administration resulted in enhanced in vivo BLI signals in the mouse model of S. 
aureus bacteremia in vivo (Fig. 4), similar enhancement might occur in other preclinical models of S. aureus infec-
tion. A previously described S. aureus skin infection model was employed in which a bioluminescent S. aureus 
strain was inoculated intradermally (i.d.) into the dorsal back skin of mice and the ensuing in vivo BLI signals were 
measured (IVIS Lumina III)22. This model was performed with AH4826 (lux + luc) (1 × 108 CFU) ± D-Luciferin 
administration (Fig. 5A,B). There were no differences between the in vivo BLI signals ± D-Luciferin for the entire 
10-day course of infection.
As an alternative preclinical S. aureus infection model, a S. aureus orthopaedic implant associated infection 
(OIAI) model in rabbits was also evaluated59. This model involved performing a medial parapatellar arthrotomy 
on the right rabbit knee, drilling a hole in the distal femur, inoculating a bioluminescent S. aureus strain into the 
intramedullary femoral canal and surgically placing of an orthopaedic-grade titanium locking peg into the canal 
prior to closure. The ensuing in vivo BLI signals from the infected post-surgical knees were measured noninva-
sively (IVIS Lumina III). This model was performed with AH4826 (lux + luc) (1 × 104 CFU) ± D-Luciferin admin-
istered prior to in vivo BLI (Fig. 5C,D). There was no difference between the in vivo BLI signals ± D-Luciferin for 
the entire 7-day course of the S. aureus OIAI.
To determine whether the AH4826 (lux + luc) bacteria maintained the luc plasmid construct after the in vivo 
infection, the infected skin tissue on day 10 (Fig. 5B) was homogenized and ex vivo CFU were cultured on plates 
overnight. BLI of the plates was performed ± the addition of D-Luciferin to the surface of the plates with no 
filter (open) and with 520, 570, 620, 670 and 710 nm emission filters (IVIS Lumina III) as in Fig. 3A (Fig. 5E). 
The same pattern of BLI signals with and without the addition of D-Luciferin was observed as was with the in 
vitro mid-logarithmic phase bacteria in Fig. 3A, indicating that the ex vivo bacteria maintained the luc construct 
following the 10-day in vivo skin infection. Taken together, in both the S. aureus skin infection mouse model and 
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the S. aureus OIAI rabbit model, the administration of D-Luciferin did not further enhance the in vivo BLI signals 
of AH4826 (lux + luc). Furthermore, the lack of enhancement of the BLI signals by administration of D-Luciferin 
was not due to loss of the luc plasmid construct in vivo as ex vivo bacterial cultures had the same pattern of BLI 
signals ± D-Luciferin as the initial mid-logarithmic phase bacteria prepared in vitro.
Figure 3. In vitro lux versus luc BLI signals through tissue. (A) AH4826 (lux + luc) was cultured on bacterial 
culture petri dishes overnight and BLI was performed for a 30 second acquisition time at 37 °C without (top 
panels [lux signals]) and with the addition of D-Luciferin (600 ng/200 µL PBS pipetted directly onto the surface 
of the plates) (bottom panels [lux + luc signals]) on an IVIS Lumina III (PerkinElmer) (n = 3 replicate plates 
with 2 iterations). Representative BLI signals are provided with no filter (open) and with 520, 570, 620, 670, 
710 and 790 nm emission filters. (B) AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), USA300 LAC::lux, 
LAC4303 (lux) and Xen36 (lux) (all 1 × 109 CFU) were cultured in 96-well plates (n = 3 replicate wells for each 
condition with 2 iterations). BLI was performed for a 1 minute acquisition time at 37 °C in an IVIS Lumina III 
(PerkinElmer) without (none) or with different thicknesses of tissue (sliced cooked ham: none, 5.25, 10.5, 15.75 
and 21.0 mm) placed on top of the plate covers ± different concentrations of D-Luciferin (0.03–2.4 mg/280 µL 
TSB) added to the wells. Representative BLI signals are shown. n.t. = not tested.
7Scientific RepoRtS |         (2019) 9:16663  | https://doi.org/10.1038/s41598-019-52982-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 4. In vivo BLI of lux versus luc in a S. aureus bacteremia mouse model. A high inoculum (1 × 107 CFU, 
20% lethal dose) of AH4826 (lux + luc) or LAC4303 (lux) was injected intravenously in mice (n = 3 mice/
group). On day 3, in vivo BLI signals were acquired before (−5 minutes) and at the indicated time points (up 
to 65 minutes) after administration of D-Luciferin (150 mg/kg s.c.) (IVIS Lumina III, PerkinElmer). (A,D) 
Representative images of in vivo BLI of the ventral (A) and dorsal (D) sides of the mice. (B,E) In vivo BLI signals 
(photons/s) ± SEM of the ventral (B) and dorsal (E) sides of mice inoculated with AH4826 ± administration 
D-Luciferin (150 mg/kg s.c.). (C,F) In vivo BLI signals (photons/s) ± SEM of the ventral (C) and dorsal (F) sides 
of mice inoculated with AH4826 (lux + luc) or LAC4303 (lux) ± administration of D-Luciferin (150 mg/kg 
s.c.) at 15–25 minutes prior to imaging the mice. †P < 0.01 between indicated groups, as calculated by a 2-tailed 
Mann–Whitney U test (C,F).
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Anatomical co-registration of in vivo BLi signals of lux versus luc. Since in vivo BLI of AH4826 
(lux + luc) after D-Luciferin administration resulted in enhanced signal detection in the mouse model of S. aureus 
bacteremia in vivo from bacteria that disseminated to internal organs (Fig. 4), this model was used to deter-
mine whether 3D lux and luc signals could be co-registered with computed tomography (CT) images of the 
mice using the IVIS Spectrum-CT imaging system (PerkinElmer). The S. aureus bacteremia model with AH4826 
(lux + luc) was performed as in Fig. 4 but with a lower (sub-lethal) inoculum (1 × 106 CFU) because the 3D IVIS 
Spectrum-CT imaging system has greater sensitivity for detecting in vivo BLI signals compared with the 2D IVIS 
Lumina III imaging system, which was used to acquire all other BLI data. On day 3 post-inoculation, the in vivo 
Figure 5. In vivo BLI of lux versus luc in additional models of S. aureus infection. (A,B) A mouse model of S. 
aureus skin infection was performed with inoculation of AH4826 (lux + luc) (1 × 108 CFU) i.d. into the back 
skin of mice (n = 10 mice/group). In vivo BLI imaging was performed ± administration of D-Luciferin (150 mg/
kg s.c.) at 15–25 minutes prior to imaging the mice (n = 10/group). (A) Representative in vivo BLI. (B) In vivo 
BLI signals (photons/s) ± SEM. (C–E) A rabbit model of S. aureus orthopaedic implant associated infection 
(OIAI) was performed with inoculation of AH4826 (lux + luc) (1 × 104 CFU) into a femoral intramedullary 
canal prior to surgical placement of an orthopaedic-grade titanium locking peg (n = 6 rabbits/group) and in 
vivo BLI imaging was performed ± administration of D-Luciferin (150 mg/kg s.c.) at 15–25 minutes prior to 
imaging the rabbits. (C) Representative in vivo BLI. (D) In vivo BLI signals (photons/s) ± SEM. (E) Skin tissue 
from day 10 was homogenized and ex vivo CFU of AH4826 (lux + luc) was cultured on bacterial culture petri 
dishes overnight (n = 5 replicates) and BLI was performed for a 30 second acquisition time at 37 °C ± the 
addition of D-Luciferin (600 ng/200 µL PBS pipetted directly onto the surface of the plates) on an IVIS Lumina 
III (PerkinElmer) and representative BLI signals are provided with no filter (open) and with 520, 570, 620, 
670 and 710 nm emission filters. *P < 0.05 between ± administration of D-Luciferin, as calculated by a 2-way 
ANOVA (B,D). n.s. = not significant.
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BLI signals of lux only (i.e., no D-Luciferin administration) resulted in dim bladder signals on the ventral sides 
of the mice and dim signals from the kidneys on the dorsal sides of the mice (Fig. 6A). Additional representative 
images of 3 of the 10 mice in this experiment (with similar results) imaged on the 2D IVIS Lumina III are also 
provided (Fig. S4). In contrast, after D-Luciferin administration, substantially increased in vivo BLI signals could 
be detected from the middle and lower back on the dorsal sides of the mice (Fig. 6A). Indeed, the in vivo BLI sig-
nals after D-luciferin were 4-fold (day 1) to 15-fold (day 3) greater than without D-Luciferin on the ventral sides 
of the mice and 4-fold (day 1) to 70-fold (day 3) greater than without D-Luciferin of the dorsal sides of the mice 
(Fig. 6B). On day 3, mice were euthanized and ex vivo CFU were enumerated after overnight culture of organ 
homogenates of the right kidney, left kidney, liver and heart. Overall, there were higher CFU isolated from the 
left and right kidneys (geometric mean = 2.89 × 104 CFU and 1.29 × 103 CFU, respectively) compared with CFU 
isolated from the liver (geometric mean = 8.97 × 102 CFU) or heart (geometric mean = 1.86 × 102 CFU) (Fig. 6C).
Figure 6. 3D localization in vivo BLI of lux versus luc in a S. aureus bacteremia mouse model. A sub-lethal 
inoculum (1 × 106 CFU) of AH4826 (lux + luc) was injected intravenously in mice (n = 10 mice/group) and 
mice were imaged ± administration of D-Luciferin (150 mg/kg s.c.) at 15–25 minutes prior to in vivo BLI. (A) 
Representative in vivo BLI images of the dorsal sides of the mice on day 3 obtained using the 2D IVIS Lumina III 
imaging system (PerkinElmer). (B) In vivo BLI signals (photons/s) ± SEM of the ventral (left) and dorsal (right) 
sides of mice. (C) Mice were euthanized on day 3 and right and left kidneys, liver and heart were harvested 
and homogenized and the ex vivo CFU were enumerated after overnight culture on plates. Each symbol is an 
individual mouse. Light blue bars = geometric mean. LOD = limit of detection [10 CFU]). (D,E) Representative 
2D and 3D in vivo BLI images of the dorsal sides of the mice (n = 10 mice) on day 3 obtained using the IVIS 
Spectrum-CT imaging system (PerkinElmer). *P < 0.05 between ± administration of D-Luciferin, as calculated 
by a 2-way ANOVA (B).
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To provide noninvasive information about the anatomic source of the in vivo BLI signals, in vivo BLI and CT 
images of 5 mice were co-registered on day 3 after the bacterial inoculation (Fig. 6D,E). Representative 2D in 
vivo BLI images (Fig. 6D [left panels]) and 3D in vivo BLI signals co-registered with the CT image (Fig. 6D [right 
panels] and Movies S1 and S2) are shown of a single mouse that had a dim signal from the right kidney without 
D-Luciferin (Fig. S5A and Movie S1) and a markedly increased signal from the right kidney after D-Luciferin 
administration (Fig. S5B and Movie S2). In addition, representative 2D in vivo BLI images (Fig. 6E [left panels]) 
and 3D in vivo BLI signals and CT image co-registration (Fig. 6E [right panels]) of a single mouse that had no 
signals without D-Luciferin and had a detectable signal from the right axillary/chest regions after D-Luciferin 
administration (Fig. S6 and Movie S3). Taken together, 3D in vivo BLI along with CT image co-registration was 
able to localize the source of the lux and luc signals. Importantly, administration of D-Luciferin to provide addi-
tional luc signals provided the new capability to visualize and co-register the source of in vivo BLI signals that 
could not be detected at all with the lux signals alone.
Sensitivity and duration of the in vivo BLi signals of the luc construct in the mouse model of S. 
aureus bacteremia. Since the in vivo BLI signals from strain AH4826 (lux + luc) after D-Luciferin admin-
istration were more than 100-fold greater than S. aureus strains expressing only the lux construct (Fig. 4C,F), the 
lower limit of sensitivity for in vivo BLI signals of AH4775 (luc) was determined. To accomplish this, the mouse 
model of S. aureus bacteremia was performed with the sub-lethal inoculum (1 × 106 CFU) of AH4775 (luc). At 
16-hours post-intravenous inoculation, D-Luciferin was administered and after 20 minutes, in vivo BLI signals 
from regions of interests overlying the right and left kidneys on the dorsal sides of the mice were acquired (IVIS 
Lumina III) with a longer (5 minute) acquisition time. All mice were immediately euthanized, each kidney was 
harvested and ex vivo CFU were enumerated. The in vivo BLI and ex vivo CFU from each of the right and left 
kidneys were graphed on a dot plot (Fig. 7A,B). Using the IVIS Lumina III imaging system with the lower limit 
of detection (LOD) of 1 × 104 photons/s, there was a range of sensitivity in which the in vivo BLI signals reached 
the LOD for the mouse with 4.2 × 103 CFU isolated from the kidneys (as well as all mice with lower ex vivo CFU) 
whereas the in vivo BLI signals of the mouse with 3.3 × 104 CFU isolated from the kidneys could be detected 
(as well as all mice with higher ex vivo CFU) (Fig. 7A,B). Therefore, the LOD for in vivo BLI signals of AH4775 
(luc) was approximately 3 × 104 CFU. Importantly, there was a high level of correlation between in vivo BLI and 
ex vivo CFU of AH4775 (luc) (correlation coefficient of determination of R2 = 0.9924) (Fig. 7B). In addition, it is 
important to assess how long can the bioluminescent signals of AH4775 (luc) be detected in vivo. Therefore, as 
a proof-of-concept, the same mouse model of S. aureus bacteremia was performed in 2 representative mice with 
the sub-lethal inoculum (1 × 106 CFU) of AH4775 (luc) and the in vivo BLI signals from the dorsal sides of the 
mice were monitored weekly. In vivo BLI imaging was performed 20 minutes after D-Luciferin administration 
Figure 7. The sensitivity of detection of AH4775 (luc) by in vivo BLI in the S. aureus bacteremia mouse model. 
Sixteen hours post-intravenous inoculation of 1 × 106 CFU of AH4775 (luc) in mice (n = 8 mice), D-Luciferin 
(150 mg/kg s.c.) was administered and after 20 minutes in vivo BLI signals was performed on the dorsal sides of 
the mice and in vivo BLI signals were acquired as total flux (photons/s) within region of interests corresponding 
to the right and left kidneys (IVIS Lumina III). Mice were then immediately euthanized and the right and left 
kidneys were separately isolated to determine the ex vivo CFU. (A) Representative images of in vivo BLI signals 
of a mouse with the highest CFU but below the level of detection (LOD) of the IVIS Lumina III (left, red arrow) 
and a mouse with the lowest detectable in vivo BLI signal from the left kidney that was above the LOD (right, 
black arrow). (B) Correlation between in vivo BLI (total flux [photons/s]) and ex vivo CFU from the right and 
left kidneys of the mice (n = 8 mice) with the red and black arrows denoting the representative mice shown 
in (A), respectively. LOD = 1 × 104 photons/s (horizontal black dashed line). The pink boxed area represents 
the range of sensitivity of detection from the highest CFU that was not detected (4.2 × 103 CFU) to the lowest 
CFU that was detected (3.3 × 104 CFU) by in vivo BLI. The linear regression line and correlation coefficient of 
determination (R2 = 0.9924) of in vivo BLI and ex vivo CFU of AH4775 (luc) are shown.
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from the dorsal backs of the mice on a weekly basis and the experiment was arbitrarily ended at 3 weeks because 
bioluminescent signals were still detected in both mice (Fig. S7A). At the 3-week time point, the mice were euth-
anized and ex vivo CFU from the kidneys were isolated and cultured on plates. The in vivo BLI and ex vivo CFU 
from each of the right and left kidneys were graphed on a dot plot (Fig. S7B). The plates were then sprayed with 
D-Luciferin and imaged in the IVIS Lumina III and in one mouse 100% of the ex vivo CFU of AH4775 (luc) on 
the plates from both kidneys still emitted a bioluminescent signal whereas the other mouse had 96% and 64% 
of ex vivo CFU of AH4775 (luc) on the plates from the left and right kidneys, respectively, still emitted a biolu-
minescent signal (Fig. S7C). These data indicate that the in vivo BLI signals from AH4775 (luc) could still be 
detected for at least 3 weeks of an in vivo bacteremia infection and the luc plasmid construct was relatively stable, 
as 64–100% of the ex vivo bacteria isolated still maintained the ability to produce bioluminescent signals.
Mouse model of a mixed S. aureus and P. aeruginosa wound infection mouse model. The 
AH4775 (luc) strain might also represent a technological advance to study the in vivo dynamics of the bacterial 
burden in a mixed infection model with different lux-expressing bacterial species, if the wavelengths of in vivo 
BLI signals from luc and lux signals could be spectrally unmixed. As a proof-of-concept, a mouse model of a 
mixed full-thickness wound infection with S. aureus and P. aeruginosa was modified from a previously established 
model in which the S. aureus inoculum was 10-fold higher than the P. aeruginosa inoculum60,61. For this exper-
iment, a 6-mm punch biopsy excisional wound was performed on the dorsal backs of mice and the wound bed 
was immediately inoculated with S. aureus AH4775 (luc) (2 × 106 CFU) and P. aeruginosa Xen41 (lux) (2 × 105 
CFU) (PerkinElmer). After D-Luciferin (150 mg/kg s.c.) administration and performing in vivo BLI of the mice, it 
was determined that the 670 nm and 520 nm emission filters of the IVIS Lumina III were able to spectrally unmix 
the luc and lux signals, respectively, with no appreciable overlap of the bioluminescent signals. Therefore, in vivo 
BLI signals of AH4775 (luc) and Xen41 (lux) were monitored using these two filters over the course of the 7-day 
infection (Fig. 8A,B). The in vivo BLI signals of AH4775 (luc) remained very stable with a slight decrease (12%) 
in signals from 6.82 × 105 ± 1.9 × 105 photons/s on day 1 to 6.02 × 105 ± 2.3 × 105 photons/s on day 7. In contrast, 
the in vivo BLI signals of Xen41 (lux) increased by approximately 2-fold from 1.0 × 106 ± 0.42 × 106 photons/s on 
day 1 to 2.44 × 106 ± 1.1 × 106 photons/s on day 3 and 1.83 × 106 ± 0.75 × 106 on day 7. It should be noted that the 
in vivo BLI signal intensity for AH4775 (luc) in the model was lower than Xen41 (lux), which was likely due to the 
use of the 670 nm filter (which was above the peak wavelength of the luc signal following D-Luciferin administra-
tion [Table 2]) or due to less bioavailability of D-Luciferin at the site of the mixed infection in this in vivo wound 
model. On day 7, the mice were euthanized and ex vivo CFU were isolated and cultured on plates. The plates were 
then sprayed with D-Luciferin and imaged (IVIS Lumina III) using the same 670 nm and 520 nm emission filters 
to distinguish between CFU of AH4775 (luc) and Xen41 (lux), respectively (Fig. 8C). The CFU were enumerated 
and there was a non-significant trend toward slightly increased CFU of AH4775 (luc) (geometric mean: 1.5 × 107 
CFU) compared with Xen41 (lux) (geometric mean: 3.2 × 106 CFU) (P = 0.095) (Fig. 8D). Taken together, these 
data indicate that a luc-expressing S. aureus strain could be used with a different lux-expressing bacterial strain 
(e.g., P. aeruginosa Xen41) to noninvasively and longitudinally monitor the dynamics of the bacterial burden of 
each bacterial strain in a mixed infection model.
Discussion
S. aureus bacteremia infections are a major clinical problem, especially since the mortality has remained 
extremely high and the treatment has been complicated by virulent and multi-drug resistant MRSA strains3–6. To 
better study these infections in preclinical animal models, we generated new S. aureus strains in the well-studied 
community-acquired MRSA strain USA300 LAC background that express lux, CBR-luc or both lux and CBR-luc 
in the same strain, including AH4807 (lux), AH4775 (luc) and AH4826 (lux + luc), respectively. In AH4775 (luc) 
and AH4826 (lux + luc), the CBR-luc plasmid construct (with the luc gene is expressed under the strong consti-
tutive S. aureus promoter hprK/lgt) was relatively stable, as it was maintained in the majority of progeny after a 
3-week in vivo experiment. To the best of our knowledge, this is the first report that has successfully been able 
to generate a CBR-luc expressing S. aureus strain AH4775 (luc) and a dual lux and CBR-luc expressing S. aureus 
strain AH4826 (lux + luc).
We found that AH4807 (lux) with the newly generated luxCDABEG construct integrated in the S. aureus 
chromosome had relatively similar in vitro bacterial growth and bioluminescent signals as previously generated 
lux expressing S. aureus strains USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (Figs 2 and S1). The lux and 
luc constructs could also be introduced into other S. aureus strains, including USA400 MW2 and Newman, 
demonstrating the broader utility of these constructs. While LAC4303 (lux) yielded the highest luminescence 
over time, the new AH4807 (lux) construct was more stably integrated in the chromosome (Fig. S1). Regarding 
tissue penetration, LAC4303 (lux) and Xen36 (lux) could be visualized through approximately 5 mm of tissue 
(sliced ham) whereas none of the signals from the lux expressing strains could be visualized through 10.5 mm of 
tissue. However, after adding D-Luciferin to cultures of AH4775 (luc) and AH4826 (lux + luc), there was mark-
edly enhanced bioluminescent signals in the 96-well plate assay (Fig. 2) and greatly increased tissue penetration, 
allowing visualization through >2 cm of tissue with AH4826 (lux + luc). Therefore, the addition of the luc con-
struct provided the improved capability of detecting bioluminescent signals through an increased thickness of 
tissue to a much greater extent than any of the S. aureus lux expressing strains.
Given the increased bioluminescent signals and tissue penetration of AH4826 (lux + luc) in vitro, we investi-
gated this particular strain in an in vivo model of S. aureus bacteremia. Without the administration of D-Luciferin, 
only dim in vivo BLI signals from lux could be detected from the bladder and kidneys on the ventral and dorsal 
sides of the mice, respectively. However, following administration of D-Luciferin, substantially increased in vivo 
BLI signals (up to 2 logs) could be visualized from the kidneys, liver and bladder on the ventral sides of the mice 
as well as increased signals from the kidneys on the dorsal sides of the mice. Most impressively, the 3D in vivo 
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BLI co-registration with the CT imaging resulted in improved detection of in vivo BLI signals from the kidneys. 
Moreover, in a single mouse there was a focus of a bacterial dissemination in the right axillary/chest region that 
could only be detected after administration of D-Luciferin. Taken together, the administration of D-Luciferin 
and ensuing luc signals greatly enhanced the capability of detecting in vivo BLI signals from bacteria that dis-
seminated to the organs and tissues in the mouse model of S. aureus bacteremia. In the bacteremia model, the 
luc-expressing S. aureus strain AH4775 (luc), following D-Luciferin administration, had a high level sensitivity 
of detection of the bacteria burden in the kidneys by in vivo BLI imaging, allowing as few as 3.3 × 104 CFU to be 
detected whereas 4,200 CFU could no longer be detected in the IVIS Lumina III. Furthermore, the in vivo BLI 
signals of AH4775 (luc) after D-Luciferin administration could be detected in the kidneys at least 3-weeks after 
Figure 8. Dual in vivo BLI monitoring of a mixed S. aureus and P. aeruginosa in vivo wound infection mouse 
model. A excisional wound mixed infection model by performing a 6-mm punch biopsy on the backs of mice 
and the wound beds were inoculated with S. aureus AH4775 (luc) (2 × 106 CFU) and P. aeruginosa Xen41 (lux) 
(2 × 105 CFU) (n = 5 mice). The mixed wound infection was followed for 7 days and CFU from the wounds 
were harvested, plated, cultured and enumerated. To distinguish between the in vivo BLI signals of AH4775 
(luc) versus Xen41 (lux), the respective 670 nm and 520 nm emission filters (IVIS Lumina III) were used 
because there was no overlap between the luc and lux bioluminescent signals. (A) Representative images of 
the in vivo BLI signals from AH4775 (luc) and Xen41 (lux) from the wounds. (B) Mean in vivo BLI signals of 
AH4775 (luc) and Xen41 (lux) quantified as total flux (photons/s) ± SEM. (C) Representative in vivo BLI of 
bacterial culture plates possessing CFU of AH4775 (luc) and Xen41 (lux) using the 670 nm and 520 nm emission 
filters, respectively. (D) Mean CFU of AH4775 (luc) and Xen41 (lux), with horizontal bars = geometric mean. 
*P < 0.05 between AH4775 (luc) and Xen41 (lux), as calculated by a 2-way ANOVA (C). n.s. = not significant 
(P = 0.095), as calculated by a 2-tailed Mann–Whitney U test (D).
13Scientific RepoRtS |         (2019) 9:16663  | https://doi.org/10.1038/s41598-019-52982-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
the bacterial inoculation and most of ex vivo CFU maintained the ability to produce luc bioluminescent signals 
after the 3-week in vivo experiment (ranging from 64–100%). Nonetheless, for long-term in vivo studies, the in 
vivo BLI signals of the plasmid-based luc construct might underestimate the actual in vivo bacterial burden and 
therefore our future studies will evaluate whether the luc construct could be inserted into the bacterial chromo-
some for improved stability.
The improved ability to detect in vivo BLI signals in the mouse model of S. aureus bacteremia model is likely 
due to a combination of increased light production by the luc construct as well as the longer wavelength of light 
produced (614 nm) that enhanced tissue penetration. In the future, alternative substrates for the same luc con-
struct in AH4775 (luc) and AH4826 (lux + luc) could be evaluated, such as the alkylaminoluciferins, aminolucif-
erins, naphthyl-based and AkaLumine-HCl luciferin analogs, luciferase substrates that can produce even longer 
wavelengths of light (up to and exceeding 730 nm), possibly allowing even greater tissue penetration than with 
D-Luciferin58,62–64. These other substrates might be particularly useful in mouse models of S. aureus bacteremia 
to detect the low bacterial CFU that are present in liver and heart (~102 CFU range) and potentially other dissem-
inated organs and tissues. These analogs (administered systemically or perhaps locally [e.g., topical application 
or by local injection at the site of infection]) might also be able to enhance the signal of luc-expressing S. aureus 
strains over that of lux-expressing S. aureus strains, which might be especially useful in enhancing the signals in 
the mouse model of S. aureus skin infection and the rabbit orthopaedic implant model. These further enhance-
ments and optimization of the luc signals will be the subject of our future work. In addition, the specific S. aureus 
luc construct developed in this study could be further modified with species-specific promoters and stable plas-
mid constructs so that it could be used in other Gram-positive bacteria, such as S. epidermidis (in which existing 
lux signals are dim, especially in biofilms38,46), Streptococcus pyogenes and Streptococcus pneumoniae to provide 
an alternative to lux expressing strains for better in vivo BLI detection in preclinical animal models of infection 
with these bacteria.
For in vivo BLI, the S. aureus luc signals were expected to be superior to lux signals because of the longer 
peak wavelength of the bioluminescent signals from CBR-luc that would have better tissue penetration. Indeed, 
CBR-luc has been shown to enhance in vivo BLI signals in preclinical mouse models with other microorgan-
isms, including Listeria monocytogenes, Mycobacterium tuberculosis, and Candida albicans47,50,51. However, when 
AH4826 (lux + luc) was evaluated in a S. aureus skin infection mouse model and in a S. aureus OIAI rabbit model, 
the administration of D-Luciferin did not enhance the in vivo BLI signals produced by lux alone. Although the 
reason for this is not entirely clear, the bioluminescent signals from luc are dependent on the bioavailability of the 
D-Luciferin substrate, which was likely higher in the organs in the bacteremia model compared with the sites of 
the bacterial infection in the skin or OIAI models. This and other possibilities will be evaluated in our future work 
as they are beyond the scope of this initial report. Nonetheless, our results strongly suggest that a bioluminescent 
S. aureus strain such as AH4826 (lux + luc) would be extremely versatile as it would take advantage of signals 
from both lux and luc for improved in vivo BLI in different models of S. aureus infection.
It should also be mentioned that lux expressing bacteria and luc expressing bacteria can be used in conjunc-
tion with in vivo BLI as the different wavelengths of bioluminescent light from each strain can be spectrally 
unmixed. For S. aureus, the interactions of two or more bacteria by using luc versus lux expressing bacteria has 
important translational relevance as many S. aureus infections in humans are polymicrobial, including burns, 
chronic wounds, diabetic foot ulcers and surgical site infections65. Specifically, in various preclinical models of 
these polymicrobial infections, in vivo BLI could be used to simultaneous study S. aureus strain AH4775 (luc) 
along with another lux expressing bacterial strain (e.g., Pseudomonas aeruginosa, Streptococcus pneumoniae and 
Streptococcus pyogenes, Haemophilus influenzae or Enterococcus faecalis) to provide new insights into coopera-
tive and competitive interactions between the different bacterial species with respect to bacterial growth, viru-
lence and antibiotic susceptibility. As a proof-of-concept, we performed a mouse model of a mixed full-thickness 
wound infection with S. aureus AH4775 (luc) and P. aeruginosa Xen41 (lux). Using the 670 nm and 520 nm emis-
sion filters of the IVIS Lumina III, the S. aureus luc signals and P. aeruginosa lux signals could be spectrally 
unmixed, which permitted the noninvasive and longitudinal monitoring of the dynamics of the bacterial bur-
den of each bacterial strain in this mixed infection model. Similar approaches have been previously used to 
study mutant versus wildtype M. tuberculosis strains during a pulmonary infection in mice47 and to investigate 
Lactobacillus plantarum versus Lactococcus lactis persistence in intestinal compartments of mice48.
Taken together, the development of luc and lux + luc expressing S. aureus strains provided increased biolumi-
nescent signals with deeper tissue penetration for improved in vivo BLI to study organ dissemination during a 
preclinical S. aureus bacteremia infection in mice. This study also provided the proof-of-concept of combining lux 
and luc constructs in the same bacterial strain AH4826 (lux + luc) to optimize the detection of in vivo BLI signals 
in different models of S. aureus infections. Therefore, the luc and lux + luc expressing S. aureus strains developed 
in this study represent a technological advance for improved in vivo BLI of preclinical S. aureus infection models 
to help provide new insights in the pathogenesis of the infection as well as evaluate novel therapeutic and diag-
nostic modalities.
Methods
construction of a lux expressing S. aureus strain. A luxCDABEG gene sequence, derived from the 
bioluminescent bacterial insect pathogen Photorhabdus luminescens (GenBank: MYFJ01000025.1), was synthe-
sized (GenScript) with Gram-positive ribosome binding sites at the start of each respective gene, all common 
restriction enzyme sites were removed and PCP25 and PCAP promoters introduced at the start of this operon66. This 
DNA sequence was then amplified using Phusion DNA polymerase (NEB) and primers lux promoter (prom) 
5′XbaI (GTT GAT TCT AGA GAT CTC GAG ATC TGC AAG ATC C) and luxG 3′EcoRI (GAA GTT GAA TTC 
TTA AAT AAA TTC GAA AGC ATC ACC ATA CAT G). The product was digested with XbaI and EcoRI before 
ligating into pLL2952 to generate pHC125. The ligation reaction was transformed into E. coli DH5α, selecting 
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with LB supplemented with 50 μg/mL spectinomycin. Positive clones were identified by bioluminescence, and 
the plasmids were isolated and electroporated into S. aureus RN4220 containing pLL278752. S. aureus RN4220 
colonies with chromosomally integrated pHC125 were selected on TSB supplemented with 1 μg/mL tetracycline. 
The integrated luxCDABEG cassette was then transduced into S. aureus strains USA300 LAC strain (AH126353), 
USA400 MW254 and Newman55 using phage 1167, generating strain AH4807 (lux), AH4821 (lux) and AH5016 
(lux), respectively (see Table 1).
construction of click beetle luciferase (luc)-expressing S. aureus strains. A codon optimized ver-
sion of click beetle red luciferase (luc) was synthesized (GenScript) and cloned into the S. aureus shuttle vector 
pCM2853 under the control of the S. aureus hprK/lgt promoter in multiple steps. Beginning with pCM28 express-
ing DsRed (pHC4868), the sarA promoter was replaced with the S. aureus hprK/lgt promoter. The region upstream 
of hprK was amplified from CA-MRSA LAC strain using primers Plgt 5′XbaI (GTT GTT TCT AGA GCC AAC 
TTG CAT TGT TTG TAG AA) and Plgt 3′ KpnI (GTT GTT GGT ACC CAA TTG TAT TTA TCC CTA CTC 
TTA CAT CTC). The resulting product was digested with XbaI and KpnI, and ligated into pHC48 digested with 
the same enzymes, generating pHC52. The DsRed gene was then replaced with the luc gene. Luc was amplified 
with primers Luc + RBS (CTT TAT AAG GAG GAA AAA CAT ATG GTA AAG CGT GAG AAA AAT GTC) 
and Luc 3′EcoRI (CAA CGA ATT CCT AGA TTA TTA CTA ACC GCC GG). An optimized ribosome binding 
site69 was then built onto this sequence with a second round of PCR, using primers Luc + RBS 5′KpnI (GTT TGG 
TAC CTG ATT AAC TTT ATA AGG AGG AAA AAC ATA TGG T) and luc 3′EcoRI. The product was digested 
with KpnI and EcoRI, and ligated into pHC52 digested with the same enzymes, generating pHC123. The plasmid 
was transformed into E. coli DH5α, selecting on LB supplemented with 100 μg/mL ampicillin. The luc gene was 
confirmed by sequencing and the plasmid was then moved into S. aureus RN4220 by electroporation, selecting 
on TSB supplemented with 10 μg/mL chloramphenicol. pHC123 was then transduced into S. aureus LAC, MW2 
and Newman to generate AH4775 (luc), AH5557 (luc), AH5556 (luc) respectively. In addition, the plasmid was 
transduced into the lux positive strains AH4807 (lux), AH4821 (lux) and AH5016 (lux) to generate AH4826 
(lux + luc), AH5559 (lux + luc) and AH5558 (lux + luc), respectively.
previously generated bioluminescent S. aureus strains. The previously generated lux expressing S. 
aureus strains were used. USA300 LAC::lux with the lux construct in the bacterial chromosome that was gener-
ated from the parent community-acquired MRSA USA300 LAC strain obtained from a skin infection outbreak 
in the Los Angeles County Jail and was kindly provided by Tammy Kielian (University of Nebraska)15. LAC4303 
(lux) (also designated SAP430) with the lux construct in the bacterial chromosome that was generated from the 
parent JE2 strain, which is the MRSA USA300 LAC strain cured of its native plasmids14,56. Xen36 (lux) with the 
lux construct integrated in a stable plasmid that was generated from the parent methicillin-sensitive S. aureus 
bacteremia isolate Wright (ATCC 49525)11.
Bacterial preparation. All S. aureus strains were streaked on tryptic soy agar (TSA) plates (tryptic soy broth 
[TSB] plus 1.5% bacto agar [BD Biosciences, San Jose, CA]) and grown overnight at 37 °C. Single colonies were 
selected and cultured in TSB at 240 RPM at 37 °C in a shaking incubator overnight followed a 1:50 subculture at 
37 °C in a shaking incubator for 2 hours to obtain mid-logarithmic phase bacteria. For strains AH4775 (luc) and 
AH4826 (lux + luc), to maintain the luc plasmid-based construct, all in vitro cultures were performed using TSB 
in the presence of 10 µg/mL of chloramphenicol. Bacteria were pelleted, washed and re-suspended in either TSB 
for in vitro experiments or PBS for in vivo experiments. Absorbance (A600) was used to estimate CFU for in vitro 
and in vivo experiments, which were verified by overnight culture plating on TSA plates.
P. aeruginosa Xen41 was streaked on LB plates (Luria-Bertani broth plus 1.5% bacto agar [BD Biosciences, San 
Jose, CA]). Single colonies were selected and cultured in LB at 240 RPM at 37 °C in a shaking incubator overnight 
followed a 1:50 subculture at 37 °C in a shaking incubator for 2 hours to obtain mid-logarithmic phase bacteria.
In vitro growth curves and lux versus luc bioluminescent signals for Figure S1A and Figure S2.  
All bioluminescent S. aureus strains were grown in TSB overnight at 37 °C in a shaking incubator at 240 rpm. 
Bacterial cells were harvested by centrifugation (5000 rpm for 10 minutes), washed twice in the same volume of 
phosphate buffered saline (PBS) and resuspended in TSB. Chloramphenicol (10 μg/mL) was added to cultures 
when needed to maintain plasmid stability. Absorbance at 600 nm (A600) was adjusted to 0.05 for all strains. 200 µL 
of bacterial culture were added to black 96-well plates with clear bottoms (Corning) and plates were incubated at 
37 °C with shaking in a humidified microtiter plate shaker (Stuart). A Tecan Infinite M Plex plate reader was used 
to periodically measure bacterial growth (A600) and luminescence intensity (Integration time 1,000 milliseconds). 
For Fig. S1A, values from quadruplicate wells were averaged and luminescence was expressed as relative lumi-
nescence units corrected to normalized bacterial growth (A600). The experiment was repeated three times with 
biological replicates. For Fig. S2, values from triplicate wells without or with addition of different concentrations 
(0.125–5 mg/ml) of D-Luciferin (XenoLight D-Luciferin - K+ Salt Bioluminescent Substrate, PerkinElmer) were 
averaged and luminescence was expressed as relative luminescence units (RLU). The experiment was repeated 
three times with biological replicates.
chromosomal integration stability of the lux bioluminescent construct for Figure S1B,C.  
LAC4303 (lux) and AH4807 (lux) were grown in 5 mL of TSB at 37 °C in a shaking incubator at 240 rpm overnight. 
One mL was harvested by centrifugation (5000 rpm, 10 minutes), washed twice in the same volume of PBS and 
resuspended in 700 µL TSB. Cells were diluted up to 10−6 and 100 µL were subsequently plated on three TSA plates; 
one plate was incubated at 43 °C, one at 37 °C and one at 30 °C for 18 hours. To determine whether plasmids are 
stably integrated into the chromosome, five randomly selected colonies from TSA plates incubated at 43 °C, 37 °C 
and 30 °C were resuspended in PBS, pelleted (5000 rpm, 10 minutes), resuspended in double distilled H2O (ddH2O) 
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with 0.5 mg/mL lysostaphin (AMBI Products, LLC) and incubated for 45 minutes at 37 °C. 5 µL of the cell lysate 
was used per PCR reaction (Taq DNA Polymerase, NEB). PCR reactions were performed using primers shown in 
Fig. S1B, and all primer sequences are published14,52. Loading dye (TriTrack, Thermo Scientific) was added to all 
PCR reactions and 6 µL of each PCR reaction were analyzed on a 1% agarose gel, which was stained in an ethidium 
bromide (Teknova) bath, destained in water and visualized with a UV Transilluminator (G:Box, Syngene) and 
GeneSys software (Syngene, Version 1.6.6.0). Original agarose gel images were color inverted, cropped and labeled 
using IrfanView software (Austria, Version 4.53) and Adobe Illustrator (USA, Version 23.0.3).
In vitro growth curves and lux versus luc bioluminescent signals. AH4807 (lux), AH4775 (luc), 
AH4826 (lux + luc), USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (all 1 × 104 CFU) were cultured in 
96-well black polystyrene microplates with clear bottoms that were tissue culture (TC)-treated (Corning) without 
(none) and with the addition of different concentrations (0.03–1.2 mg/240 µL/well) of D-Luciferin (XenoLight 
D-Luciferin - K+ Salt Bioluminescent Substrate, PerkinElmer) for 0–14 hours at 240 rpm at 37 °C. Absorbance 
(A600) and bioluminescent signals (photons/0.1 second) were measured every 5 minutes on a plate reader (BioTek 
H1 Synergy) (n = 4 replicates with 2 iterations). All absorbance and bioluminescent signal measurements were 
blanked to control wells containing the same D-Luciferin concentration.
In vitro lux versus luc BLi signals from bacterial culture plates. AH4826 (lux + luc) was cultured 
on TSA petri dishes (100 × 15 mm) overnight at 37 °C ± addition of 600 ng D-Luciferin (PerkinElmer) in 200 µL 
PBS pipetted directly onto the surface of the plates. All plates were imaged for a 30 second acquisition time (IVIS 
Lumina III, PerkinElmer) with no filter (open) and with 520, 570, 620, 670, 710 and 790 nm emission filters and 
representative images of the BLI signals are provided (n = 3 replicates with 2 iterations).
In vitro lux versus luc BLi signal through tissue. AH4807 (lux), AH4775 (luc), AH4826 (lux + luc), 
USA300 LAC::lux, LAC4303 (lux) and Xen36 (lux) (1 × 109 CFU) were cultured in 96-well black polystyrene 
microplates with clear bottoms that were TC-treated (Corning) without (none) and with the addition of different 
concentrations (0.03–2.4 mg/280 µL TSB/well) of D-Luciferin (PerkinElmer). To determine tissue penetration of 
the BLI signals, different thicknesses (5.25–21.0 mm) of sliced cooked ham (Lunch Mate) were placed on top of 
the plate covers prior to BLI. All plates were imaged for a 1 minute acquisition time at 37 °C (IVIS Lumina III) and 
representative images of the BLI signals are provided (n = 3 replicate wells for all conditions with 2 iterations).
Animals (mice and rabbits).  All mouse and rabbit studies were approved by the Johns Hopkins University 
Animal Care and Use Committee according to the guidelines and regulations described in the Guide for the Care 
and Use of Laboratory Animals (National Academies Press, 2011). All mice and rabbits were maintained and 
housed under specific pathogen–free conditions at our animal facility accredited by the American Association 
for the Accreditation of Laboratory Animal Care (AAALAC) at Johns Hopkins. Six to 8 week-old female C57BL/6 
mice (Jackson Laboratories, Bar Harbor, ME) were used in all in vivo mouse experiments. Ten to 16 week-old 
male Dutch Belted rabbits (Robinson Services, Mocksville, NC) (~2 kg body weight) were used in all in vivo rabbit 
experiments.
Mouse model of S. aureus bacteremia. Mice were anesthetized (inhalation 2% isoflurane) and all hair 
on the dorsal and ventral skin was shaved with clippers. Anesthetized mice were inoculated intravenously (i.v.) 
with either a 20–30% lethal inoculum (1 × 107 CFU) or a sub-lethal inoculum (1 × 106 CFU) of LAC4303 (lux) or 
AH4826 (lux + luc) in a 100 μL volume of PBS using a 29-gauge insulin syringe via the retro-orbital vein. For the 
1 × 107 CFU inoculum, on day 3 post-inoculation, in vivo BLI was performed on anesthetized mice (2% isoflu-
rane) from the ventral and dorsal sides of the mice before (−5 minutes) and after injection (at the indicated time 
points between 0 and 65 minutes) of D-Luciferin (150 mg/kg administered subcutaneously [s.c.]) for a 1 minute 
acquisition time at 37 °C (IVIS Lumina III). For the 1 × 106 CFU inoculum, on days 1, 2 and 3 post-inoculation, 
in vivo BLI was performed on anesthetized mice (2% isoflurane) ± administration of D-Luciferin (150 mg/kg 
s.c. given 15–25 minutes prior to imaging) for a 1 minute acquisition time at 37 °C (IVIS Lumina III). Total flux 
(photons/s) was measured within an oval region of interest (2 × 4 cm) from the ventral and dorsal sides of the 
mice using Living Image software (PerkinElmer). To provide anatomical co-registration data, for the 1 × 106 CFU 
inoculum, in vivo BLI and simultaneous CT imaging were performed on day 3 post-inoculation on anesthetized 
mice (2% isoflurane) ± administration of D-Luciferin (150 mg/kg s.c. given 15–25 minutes prior to imaging) for 
a 3 to 15 minute acquisition time (depending on signal intensity using autoexposure) at 37 °C using firefly lucif-
erase DLIT settings (600 nm, 620 nm, 640 nm filters) on an IVIS Spectrum-CT imaging system for both lux and 
luc signals (PerkinElmer). To determine the in vivo lower limit of sensitivity and duration of the in vivo BLI 
signals of AH4775 (luc), 6-week old of C57BL/6 female mice were inoculated intravenously with 1 × 106 CFU 
of AH4775 (luc). At 16-hours (sensitivity) or on a weekly basis up to 3-weeks post infection, mice were admin-
istered D-Luciferin (150 mg/kg s.c.) and after 20 minutes in vivo BLI was performed on the dorsal sides of the 
mice with a 5 minute acquisition time at 37 °C (IVIS Lumina III). Total flux (photons/s) from two separate oval 
region of interests (1.1 × 0.9 cm) overlying the right and left kidneys were measured using Living Image software 
(PerkinElmer). Mice were then immediately euthanized and the right and left kidneys were separately isolated, 
homogenized and plated overnight to enumerate the ex vivo CFU, as described below. The linear regression line 
and correlation coefficient of determination between in vivo BLI and ex vivo CFU were calculated using Prism 
(GraphPad, La Jolla, CA).
Mouse model of S. aureus skin infection. This mouse model of S. aureus skin infection was performed 
as previously described22. Briefly, the dorsal backs of anesthetized mice (2% isoflurane) were shaved and injected 
intradermally (i.d.) in the upper back skin with 1 × 108 CFU/100 μL PBS of AH4826 (lux + luc). On days 1, 3, 
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7 and 10, in vivo BLI was performed on anesthetized mice (2% isoflurane) ± administration of D-Luciferin 
(150 mg/kg s.c. given 15–25 minutes prior to imaging) for a 1 minute acquisition time at 37 °C (IVIS Lumina III). 
Total flux (photons/s) was measured within a 1 × 103 pixel circular region of interest using Living Image software 
(PerkinElmer).
Mouse model of a mixed S. aureus and P. aeruginosa wound infection mouse model. A mouse 
model of a mixed full-thickness wound infection with S. aureus and P. aeruginosa was modified from a previously 
established model in which the S. aureus inoculum was 10-fold higher than the P. aeruginosa inoculum60,61, using 
the S. aureus AH4775 (luc) strain and the P. aeruginosa (lux) Xen41 strain (PerkinElmer). Briefly, C57BL/6 mice 
were anesthetized (2% isoflurane) and the dorsal backs were shaved and the skin was surgically prepped with 
povidone-iodine and 70% alcohol. A full thickness 6-mm punch biopsy (Acuderm) was used to create a circular 
excisional full-thickness wound and AH4775 (luc) (2 × 106 CFUs/10 µL) and Xen41 (lux) (2 × 105 CFUs/10 µL) 
were sequentially pipetted into the wound bed. In vivo BLI of AH4775 (luc) and Xen41 (lux) was performed 
on anesthetized mice 20 minutes after administration of D-Luciferin (150 mg/kg s.c.) on days 1, 3, and 7 with 
a 1 minute acquisition time at 37 °C using 670 nm and 520 nm emission filters. These specific filters were used 
because the luc and lux signals from the different bacteria could be spectrally unmixed, as there was no overlap 
of signals. On day 7, mice were euthanized and the wound tissue was homogenized and plated overnight to enu-
merate the ex vivo CFU, as described below.
Ex vivo cfU enumeration. For experiments with 1 × 106 CFU of AH4826 (lux + luc), mice were euthanized 
on day 3 and right and left kidneys, liver and heart were harvested and homogenized (Pro200 Series homoge-
nizer; Pro Scientific) in 1 mL of PBS at 4 °C. Ex vivo CFU were counted after plating serially diluted organ tissue 
homogenates overnight on TSA plates. For lower limit of sensitivity and duration experiments with 1 × 106 CFU 
of AH4775 (luc), mice were euthanized at 16-hours and 3-weeks post-infection, respectively, and the right and 
left kidneys were separately harvested and homogenized (Pro200 Series homogenizer; Pro Scientific) in 1 mL of 
PBS at 4 °C and serially diluted homogenates were cultured overnight on TSA plates. D-Luciferin (30 mg/mL) 
was sprayed onto the plates and the plates were subsequently imaged in the (IVIS Lumina III) to enumerate the 
number of ex vivo CFU and to determine the percentage of CFU that still emitted a bioluminescent signal. For 
the mixed wound infection model with AH4775 (luc) and P. aeruginosa strain Xen41 (lux), mice were euthanized 
on day 7 post-infection and the wound tissue was excised with 8-mm punch biopsy tool (Acuderm). The excised 
tissue was homogenized (Pro200 Series homogenizer; Pro Scientific) in 1 mL of PBS at 4 °C and serially diluted 
homogenates were plated overnight on TSA plates. To distinguish between the CFU of AH4775 (luc) and Xen41, 
D-Luciferin (30 mg/mL) was sprayed onto the plates and the plates were subsequently imaged in the IVIS Lumina 
III using the 670 emission filter to identify and enumerate AH4775 (luc)-positive CFU and the 520 nm emission 
filter to identify Xen41 (lux)-positive CFU.
Rabbit model of S. aureus orthopaedic implant associated infection. This model of S. aureus 
orthopaedic implant associated infection (OIAI) was performed as previously described59. Briefly, rabbits were 
anesthetized via intramuscular (i.m.) injection with ketamine and xylazine (25 mg/kg and 1.5 mg/kg respec-
tively) (ZooPharm) and maintained with inhalation isoflurane (2%). Ophthalmic ointment (Optixcare eye lube) 
applied to the eyes. Sustained-release buprenorphine (ZooPharm) (0.2 mg/kg) and sustained-release meloxicam 
(Norbrook laboratories) (0.6 mg/dose) were given s.c. for analgesia. The right leg was shaved and ethanol and 
povidone-iodine (Betadine surgical scrub) (7.5%) were applied sequentially thrice. A midline incision over the 
patella was made followed by a medial parapatellar arthrotomy in which the patella was dislocated to visualize 
the femoral intercondylar notch. A 2-mm diameter hole was drilled and countersunk into the femoral medullary 
canal followed by bacterial inoculation with 1 × 104 CFU/10 μL PBS of AH4826 (lux + luc) into the intramed-
ullary canal. An orthopedic-grade titanium locking peg (2 × 24 mm) (Zimmer Biomet) was inserted into the 
femoral medullary canal so that the end was flush with the articular surface. The patella was relocated to midline 
and surgical site was closed in a layered fashion using 3–0 Vicryl sutures. On post-surgical days 1, 4 and 7, in vivo 
BLI was performed on anesthetized rabbits (ketamine and xylazine i.m. and 2% isoflurane) ± administration of 
D-Luciferin (150 mg/kg s.c. given 15–25 minutes prior to imaging) for a 5 minute acquisition time at 37 °C (IVIS 
Lumina III). Total flux (photons/s) was measured within a 3 × 4 cm oval region of interest using Living Image 
software (PerkinElmer).
Statistics. Data for multiple comparisons were calculated by 2-way ANOVA and data for single compari-
sons were compared using a 2-tailed Mann-Whitney U test. All statistical analyses were performed using Prism 
(GraphPad, La Jolla, CA). Data are presented as mean ± standard error of the mean (SEM) or geometric mean 
and values of P < 0.05 were considered significant.
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